Bayer Leverages ConcertAI’s Translational360™ Platform for AI-Driven Oncology

What You Should Know:

– ConcertAI announced a multi-year agreement with Bayer to leverage ConcertAI’s Translational360 and AI SaaS solutions, which use artificial intelligence and machine learning (AI/ML)-derived insights to accelerate clinical development in precision oncology.

– The agreement will fully leverage ConcertAI’s newly launched Translational360, an integrated research-grade longitudinal clinical molecular database that taps into the CancerLinQ network of de-identified cancer patient data from over 9 million records coming from all 50 states in the U.S.

ConcertAI Advances Oncology R&D Through Integrated AI and Multi-Modal Data Solutions

ConcertAI is a leading provider of predictive and generative AI SaaS solutions, offering real-world data research tools tailored for healthcare and life sciences. Headquartered in Cambridge, MA, the company operates globally with offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. Its mission is to accelerate clinical insights and patient outcomes through research-ready data, proprietary CARAai technologies, and scientific expertise. In partnership with over 46 top biomedical innovators, 2,000 healthcare providers, and numerous medical societies, ConcertAI delivers scalable, impactful research and AI-driven solutions across the healthcare ecosystem.

Core platforms include:

TeraRecon®, which offers advanced radiological image visualization and clinical AI decision support for MRI and CT imaging.CancerLinQ®, an ASCO-aligned initiative that provides oncology practices with automated QOPI and ASCO Certified® quality solutions, alongside SmartLinQ analytics services to enhance care quality and performance metrics.

A central innovation, Translational360, integrates clinical, genomic, transcriptomic, and whole-slide imaging (WSI) data derived from comprehensive molecular testing. This platform supports deeper phenotypical and genomic characterization, advancing translational research by enabling researchers to:

Uncover disease-specific molecular mechanismsUnderstand patient-specific treatment responsesExplore inter-patient variability crucial to novel therapeutic development

Transcriptomics, a key component of Translational360, is increasingly central to biopharma research. It enables investigators to resolve ambiguities in early-phase clinical trial outcomes by identifying both idiosyncratic positive and negative responses. Through the use of multi-modal, multi-genomic, and transcriptomic data, combined with AI-based analytics, ConcertAI supports:

The prioritization of therapeutic programs with the highest probability of successThe design of precision-informed clinical trials

According to Dr. Jeff Elton, CEO of ConcertAI, “This partnership advances causal biological inferences by integrating multi-modal and multi-molecular data with AI/ML-based approaches across the discovery-to-development continuum. It accelerates oncology pipelines and enables biopharma partners to deliver better medicines faster.” He emphasized that the collaboration builds on a longstanding relationship and is distinctive in its use of both tissue and liquid biopsy molecular data. This approach enables:

AI modeling of treatment response patterns and resistance mechanismsData-driven prioritization of clinical programsOptimization of study design based on predicted therapeutic benefit and success rates

Together, these capabilities position ConcertAI and its partners at the forefront of translational oncology innovation.